Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.

Publication ,  Conference
Armstrong, AJ; Saad, F; Shore, ND; Fizazi, K; Phung, D; Dmuchowski, C; Hirmand, M; Forer, D; Scher, HI; De Bono, JS
Published in: Journal of Clinical Oncology
May 20, 2016

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

5062 / 5062

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Saad, F., Shore, N. D., Fizazi, K., Phung, D., Dmuchowski, C., … De Bono, J. S. (2016). Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. In Journal of Clinical Oncology (Vol. 34, pp. 5062–5062). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.5062
Armstrong, Andrew J., Fred Saad, Neal D. Shore, Karim Fizazi, De Phung, Carl Dmuchowski, Mohammad Hirmand, David Forer, Howard I. Scher, and Johann S. De Bono. “Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.” In Journal of Clinical Oncology, 34:5062–5062. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5062.
Armstrong AJ, Saad F, Shore ND, Fizazi K, Phung D, Dmuchowski C, et al. Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5062–5062.
Armstrong, Andrew J., et al. “Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 5062–5062. Crossref, doi:10.1200/jco.2016.34.15_suppl.5062.
Armstrong AJ, Saad F, Shore ND, Fizazi K, Phung D, Dmuchowski C, Hirmand M, Forer D, Scher HI, De Bono JS. Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 5062–5062.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

5062 / 5062

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences